Silexion Therapeutics Corp - 8-K Filing
Silexion Therapeutics Corp reported first-quarter financial results for Q1 2026, with R&D expenses at $1.4 million (up 133% YoY) and G&A expenses at $1.4 million (up 27% YoY), resulting in a net loss of $2.7 million (up 58.8% YoY). The company announced regulatory approvals to initiate its Phase 2/3 trial for SIL204 in Israel, with the CTA submitted to Germany and planned initiation in Q2 2026. Cash balance was $2.4 million as of March 31, down from $6.0 million at year-end due to operating expenses; subsequent capital raises increased equity above Nasdaq's minimum requirement. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits (d) Exhibits 99)
Tickers: $SLXN